Appeals court splits over embryonic stem cells

gavel

The three-judge panel on a federal appeals court considering whether to overturn a ban on federal funding of embryonic stem cell research revealed a split during a hearing yesterday.

President Barack Obama’s administration is appealing a lower court decision banning federal funding of the research. During yesterday’s hearing at the U.S. Court of Appeals for the District of Columbia Circuit, two of the judges questioned the U.S. Justice Dept.’s arguments that the ban would do irreparable harm to the public interest, while a third seemed more sympathetic.

Judge Royce Lamberth of the U.S. District Court for the District of Columbia had ruled that federal funds could not be used for the the research, derailing scores of projects looking into the causes of diseases like Parkinson’s, Alzheimer’s and cystic fibrosis. Obama had sought to restore stem cell research funding from constraints imposed under the Bush administration, but Lamberth ruled that the policy violated the Dickey-Wicker Amendment, aimed at stopping the destruction of human embryos.

But Dickey-Wicker proved to be a sticky wicket for both plaintiffs and defendants when the appeals court issued a temporary stay of the Lamberth ruling.

Obama’s policy allowed the use of stem cell lines derived from frozen embryos from fertility treatments that were no longer needed and donated according to stringent ethical guidelines. The plaintiffs in the lawsuit, James Sherley and Theresa Deisher, argued that the Obama policy violated the Dickey-Wicker rules.

Beth Brinkmann, a Justice Dept. lawyer, argued that the ban would be a waste of the $64 million that’s already been spent on 24 research projects at the National Institutes of Health, according to news reports. Thomas Hungar, an attorney for the plaintiffs, called that argument speculation and maintained that no injury is imminent or irreversible.

Judge Thomas Griffith, a George W. Bush appointee, appeared to be the most skeptical of the government’s argument, saying that the judges are not hearing the case to decide the wisdom of government policy but to judge whether the research violates the Dickey-Wicker amendment.

“All $64 million is completely ruined?” Griffith asked. “They don’t keep lab notebooks?”

There are notes, Brinkmann said, but “it would be a setback for the field. Biological material would be destroyed.”

Judge Brett Kavanaugh, another George W. Bush appointee, called the government’s position “odd” and “internally inconsistent” but said it might be best to defer to the government’s arguments because of the ambiguity of the Dickey-Wicker statute.

Clinton appointee Judge Judith Rogers said that even a temporary halt to the funding could damage public interest represented by the research.

The Justice Dept. previously argued that Congress never intended for the Dickey-Wicker rules to bar all embryonic stem cell research.

"The National Institutes of Health has funded research using embryonic stem cells since 2002, and has not interpreted the Amendment to bar such grants,” according to court documents. "Fully aware of NIH practice, Congress has used the same language in reenacting the funding limitation, and has repeatedly made clear that NIH’s practice is consistent with the statute. Indeed, the relevant Committee Report for the 2010 appropriations bill, enacted after issuance of the current NIH guidelines, noted that the bill ‘should not be construed to limit Federal support for research involving human embryonic stem cells carried out in accordance with policy outlined by the President.’"

That’s because research using stem cell lines already in existence doesn’t involve the destruction of the embryos, the DOJ argued.

"The bar posited by plaintiffs and the district court has never existed," according to the documents. "[R]esearch using embryonic stem cells is not ‘research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death.’ Plaintiffs insist that this consistent interpretation reflects a ‘warped reading of the term "research,"’ which should be understood to mean a ‘systematic investigation.’ Referring to scientific research projects as ‘systematic investigations’ adds nothing to plaintiffs’ argument and does not expand research funded by NIH to include antecedent acts that were not funded by NIH."

Furthermore, the Justice Dept. argued, barring federal funding of the research will have a catastrophic impact on medical research.

"Disruption of ongoing research will result in irreparable setbacks and, in many cases, may destroy a project altogether. In contrast, the two plaintiff scientists identify no imminent irreparable injury," according to the department.

RSS From Medical Design & Outsourcing

  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]

Leave a Reply